Literature DB >> 17040995

P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production.

Eva Schepers1, Natalie Meert, Griet Glorieux, Jan Goeman, Johan Van der Eycken, Raymond Vanholder.   

Abstract

BACKGROUND: Chronic renal insufficiency is associated with the retention of solutes normally excreted by healthy kidneys. P-cresol, a prototype protein-bound uraemic retention solute, has been shown to exert toxic effects in vitro. Recently, however, it has been demonstrated that p-cresol in the human body is conjugated, with p-cresylsulphate as the main metabolite.
METHODS: The present study evaluates the effect of p-cresylsulphate on the respiratory burst activity of leucocytes.
RESULTS: P-cresylsulphate significantly increased the percentage of leucocytes displaying oxidative burst activity at baseline. Oxidative burst activity of stimulated leucocytes was however not affected. In contrast, p-cresol had no effect on the leucocytes at baseline, but inhibited leucocytes burst activity after stimulation.
CONCLUSION: The present study demonstrates, for the first time, that p-cresylsulphate, the main in vivo metabolite of p-cresol, has a pro-inflammatory effect on unstimulated leucocytes. This effect could contribute to the propensity to vascular disease in the uraemic population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040995     DOI: 10.1093/ndt/gfl584

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  89 in total

1.  Selectively increasing the clearance of protein-bound uremic solutes.

Authors:  Tammy L Sirich; Frank J-G Luo; Natalie S Plummer; Thomas H Hostetter; Timothy W Meyer
Journal:  Nephrol Dial Transplant       Date:  2012-01-09       Impact factor: 5.992

2.  Metabolomics reveals differential levels of oral metabolites in HIV-infected patients: toward novel diagnostic targets.

Authors:  Mahmoud A Ghannoum; Pranab K Mukherjee; Richard J Jurevic; Mauricio Retuerto; Robert E Brown; Masoumeh Sikaroodi; Jennifer Webster-Cyriaque; Patrick M Gillevet
Journal:  OMICS       Date:  2011-07-13

3.  Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.

Authors:  Liesbeth Viaene; Björn K I Meijers; Bert Bammens; Yves Vanrenterghem; Pieter Evenepoel
Journal:  Perit Dial Int       Date:  2013-10-31       Impact factor: 1.756

Review 4.  Challenges and opportunities for stem cell therapy in patients with chronic kidney disease.

Authors:  LaTonya J Hickson; Alfonso Eirin; Lilach O Lerman
Journal:  Kidney Int       Date:  2016-01-26       Impact factor: 10.612

5.  p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease.

Authors:  Cheng-Jui Lin; Han-Hsiang Chen; Chi-Feng Pan; Chih-Kuang Chuang; Tuen-Jen Wang; Fang-Ju Sun; Chih-Jen Wu
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

6.  Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins.

Authors:  Sunny Eloot; Eva Schepers; Daniela V Barreto; Fellype C Barreto; Sophie Liabeuf; Wim Van Biesen; Francis Verbeke; Griet Glorieux; Gabriel Choukroun; Ziad Massy; Raymond Vanholder
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

7.  Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients.

Authors:  Tammy L Sirich; Natalie S Plummer; Christopher D Gardner; Thomas H Hostetter; Timothy W Meyer
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 8.237

Review 8.  The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.

Authors:  Raymond Vanholder; Eva Schepers; Anneleen Pletinck; Evi V Nagler; Griet Glorieux
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

9.  p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients.

Authors:  Björn K I Meijers; Henriette De Loor; Bert Bammens; Kristin Verbeke; Yves Vanrenterghem; Pieter Evenepoel
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

Review 10.  The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective.

Authors:  Paula Mosińska; Martin Storr; Jakub Fichna
Journal:  Therap Adv Gastroenterol       Date:  2015-09       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.